Avery Therapeutics, Inc.

Avery Therapeutics, Inc. is a pre-clinical stage company developing regenerative therapeutics. Avery’s lead product, MyCardia, is a tissue engineered graft for treatment of chronic heart failure, a disease affecting 24M people worldwide.